国家医保局，重拳出击！

Group 1 - The National Healthcare Security Administration (NHSA) reported a case of commercial bribery involving Shanghai Haiyilai Enterprise Consulting Management Partnership, which engaged in illegal activities to promote the sales of "Dahansuan Sodium Injection" (product name: Wanmailing) in Shanghai [2][3] - The NHSA has established a credit evaluation system since 2020 to assess companies involved in bribery and illegal sales practices, aiming to ensure fair competition and protect the rights of compliant businesses [3] - The involved company, Changshan Pharmaceutical, is a key player in the heparin market and has faced challenges due to changes in the centralized procurement policy affecting its low molecular weight heparin products [4][5] Group 2 - Changshan Pharmaceutical reported a significant decline in sales for its low molecular weight heparin products, with overall sales of 15.36 million units in the first half of 2025, a decrease of 19.17% year-on-year [5] - The sales revenue for Nacouheparin Calcium Injection dropped by 36.47% to 67.76 million yuan, while Dahansuan Sodium Injection revenue fell by 27.55% to 56.51 million yuan [5] - As of January 12, 2025, Changshan Pharmaceutical's stock price was 57.79 yuan per share, reflecting a decline of 2.02% and a total market capitalization of 53.11 billion yuan [5]